Dyspepsia secondary prevention
|
Dyspepsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspepsia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Dyspepsia secondary prevention |
|
Risk calculators and risk factors for Dyspepsia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Ajay Gade MD[3]]
Overview
Dyspepsia is defined clinically as predominant epigastric pain or discomfort lasting at least one month, encompassing symptoms of epigastric pain, epigastric burning, postprandial fullness, and early satiety, occurring in the absence of an obvious structural cause.[1] Dyspepsia is among the most common reasons for primary care consultation. Using a broad clinical definition, the prevalence of dyspepsia approaches 30% at any one point in time in the general population, while application of the Rome IV criteria yields a more conservative global pooled prevalence of approximately 7–8.4% (95% CI 7.4–9.5%) across 40 countries.[2]
Dyspepsia is broadly categorized as:
- Uninvestigated dyspepsia (UD): Epigastric symptoms that have not yet been subject to diagnostic investigation.
- Investigated dyspepsia: Where an underlying cause has been identified (e.g., peptic ulcer disease, gastroesophageal reflux disease, Helicobacter pylori gastritis).
- Functional dyspepsia (FD): Dyspepsia without an identifiable organic, systemic, or metabolic cause on thorough evaluation, meeting Rome IV criteria for either postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).[3]
The Rome IV criteria define FD as one or more of: bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning, present for at least the last 3 months with symptom onset at least 6 months before diagnosis, with no evidence of structural disease to explain the symptoms.[3] PDS (postprandial symptoms) accounts for 66.6% of FD, EPS (pain-predominant) for 15.3%, and overlapping PDS/EPS for 18.1%.[4]
The global burden is higher in women (prevalence 9.0% vs. 7.0% in men) and higher in developing countries (9.1% vs. 8.0% in developed countries), and the overall prevalence has been declining from 12.4% (1990–2002) to 7.3% (2013–2020).[2]
Differentiating Dyspepsia from other Diseases
The diagnosis of functional dyspepsia requires exclusion of organic, systemic, or metabolic disorders that may present with overlapping epigastric symptoms. The following table summarizes key differential diagnoses:
| Disease | Distinguishing Features | Key Investigations |
|---|---|---|
| Peptic ulcer disease | Epigastric pain relieved by food (duodenal ulcer) or worsened by food (gastric ulcer); history of NSAID use or Helicobacter pylori infection | Upper endoscopy (gold standard); urea breath test; fecal antigen test |
| Gastroesophageal reflux disease | Predominant heartburn, acid regurgitation; symptoms worse when supine or postprandial; may overlap with dyspepsia | Clinical diagnosis; empirical proton pump inhibitor trial; ambulatory pH monitoring if needed |
| Gastroparesis | Postprandial fullness, nausea, vomiting, early satiety; often in diabetes mellitus or post-surgical context | Gastric emptying scintigraphy (4-hour solid-phase study); wireless motility capsule |
| Gastric cancer | Age ≥55 years, unexplained weight loss, dysphagia, persistent vomiting, GI bleeding, family history of gastric cancer, new-onset dyspepsia | Upper endoscopy with biopsy; computed tomography of abdomen/pelvis |
| Esophageal cancer | Dysphagia (progressive), odynophagia, weight loss, male sex, smoking, Barrett esophagus history | Upper endoscopy with biopsy; endoscopic ultrasound; computed tomography |
| Pancreatic cancer | Epigastric or back pain, jaundice, weight loss, new-onset diabetes mellitus, pancreatic insufficiency | Computed tomography of abdomen (triple phase); endoscopic ultrasound; CA 19-9; MRCP |
| Biliary tract disease / Cholelithiasis | Post-prandial right upper quadrant pain, particularly after fatty meals; crescendo-decrescendo character; nausea, vomiting | Abdominal ultrasound; liver function tests; lipase |
| Celiac disease | Diarrhea, weight loss, iron deficiency, bloating; may present without classic malabsorption | Tissue transglutaminase IgA antibodies; duodenal biopsy on endoscopy |
| Irritable bowel syndrome | Overlapping symptoms; lower abdominal cramping, altered bowel habit, relief with defecation; upper GI overlap in 26.1% | Rome IV criteria; clinical diagnosis of exclusion |
| Eosinophilic gastroenteritis | May mimic FD; associated with atopy, food allergy, peripheral eosinophilia | Upper endoscopy with gastric and duodenal biopsies (eosinophil counts) |
| Medication-induced dyspepsia | Temporal relationship to NSAID, aspirin, bisphosphonate, or iron use | Careful drug history; trial of medication withdrawal |
| Myocardial infarction / Ischemic heart disease | Atypical presentation especially in women, elderly, and diabetes mellitus; epigastric pain with radiation, diaphoresis, dyspnea | Electrocardiogram; cardiac troponins; risk factor assessment |
Screening for Dyspepsia
Who to Screen
There is no evidence supporting population-level mass screening for dyspepsia or functional dyspepsia in asymptomatic individuals. Screening and diagnostic workup is indicated when patients present with dyspeptic symptoms. The key clinical decision in the evaluation of uninvestigated dyspepsia is stratification by age, symptom pattern, and risk features to guide appropriate investigation.
The ACG/CAG (2017) joint guideline and the BSG (2022) guideline provide the principal evidence-based frameworks for this stratification.[1][3]
Alarm Features ("Red Flags")
The following alarm (or "red flag") features should prompt evaluation for organic pathology and lower the threshold for urgent upper endoscopy (esophagogastroduodenoscopy; EGD), regardless of patient age:
| Alarm Feature | Clinical Significance |
|---|---|
| Dysphagia (progressive) | Risk of esophageal or gastric cancer; requires urgent EGD |
| Unexplained significant weight loss | Risk of upper GI malignancy |
| Hematemesis or recurrent gastrointestinal bleeding | Risk of peptic ulcer, gastric cancer, or esophageal varices |
| Iron deficiency anemia (unexplained) | May signify upper GI blood loss or celiac disease |
| Persistent vomiting | May indicate obstruction or malignancy |
| Palpable upper abdominal mass or lymphadenopathy | Strongly suspicious for upper GI malignancy |
| Jaundice | Risk of pancreatic cancer, biliary obstruction, hepatocellular carcinoma |
| Family history of upper GI cancer (first-degree relative) | Increased risk for gastric cancer or esophageal cancer |
| Previous gastric surgery or known Barrett esophagus | Increased cancer risk; requires endoscopic surveillance |
Please note that the ACG/CAG guideline emphasizes that alarm features have a low positive predictive value for malignancy (each individual alarm feature, such as weight loss or anemia, carries a positive predictive value of less than 1% for malignancy in patients younger than 60 years). Alarm features confer a 2–3-fold relative increased risk of upper GI malignancy compared to dyspepsia without alarm features, but the absolute risk in individuals under 60 years remains well below 1%, making routine endoscopy for all young patients with alarm features cost-ineffective.[1] Alarm features should be assessed on a case-by-case basis and do not automatically mandate upper endoscopy in younger patients.
Age-Based Stratification for Endoscopy
Guidelines universally recommend age-based stratification as the cornerstone of the investigation strategy for uninvestigated dyspepsia:
| Age Group | Recommended Strategy | Guideline Source |
|---|---|---|
| < 60 years, no alarm features | Non-invasive Helicobacter pylori test and treat (urea breath test or fecal antigen test) as first-line. If H. pylori-negative or symptoms persist after eradication, empirical proton pump inhibitor (PPI) therapy. | ACG/CAG 2017 (Strong recommendation, High quality evidence)[1]; BSG 2022[3] |
| ≥ 60 years | Upper endoscopy (EGD) to exclude upper GI neoplasia. This is a conditional recommendation; the threshold may be lowered in higher-risk populations (e.g., high gastric cancer prevalence regions, family history). | ACG/CAG 2017 (Conditional recommendation, Very low quality evidence)[1] |
| ≥ 55 years, treatment-resistant dyspepsia or weight loss | Urgent direct-access endoscopy (within 2 weeks) per NICE NG12 guidance for suspected upper GI cancer | NICE NG12 (suspected cancer referral guidance)[5] |
| Any age with progressive dysphagia | Urgent EGD regardless of age | ACG/CAG 2017; BSG 2022; NICE NG12 |
| Any age with palpable abdominal mass | Urgent investigation (EGD and/or computed tomography) | ACG/CAG 2017; NICE NG12 |
The ACG/CAG guideline notes that the age threshold for endoscopy should be lowered in patients from high-risk gastric cancer regions (e.g., East Asia, parts of South America), and that sex may also be considered, as age-adjusted upper GI cancer risk is approximately twice as high in men as in women.[1]
Non-Invasive Testing for Helicobacter pylori
For patients under 60 years with uninvestigated dyspepsia and without alarm features, the ACG/CAG (2017) guideline provides a strong recommendation (high quality evidence) for the H. pylori test and treat strategy as initial management.[1] The BSG (2022) guideline similarly endorses non-invasive testing for H. pylori in all eligible patients with dyspepsia before initiating empirical acid suppression.[3]
Preferred non-invasive tests include:
- Urea breath test (UBT): High sensitivity (>95%) and specificity (>95%); preferred test. Requires 2-week washout from proton pump inhibitors and 4-week washout from antibiotics.
- Stool antigen test (SAT): Comparable sensitivity and specificity to UBT; useful where UBT is unavailable.
- H. pylori serology: Not recommended as an alternative to UBT or SAT due to lower specificity, inability to distinguish active from past infection, and persistence of antibody positivity after eradication.[3]
H. pylori test and treat was shown in six trials (2,399 patients) to be non-inferior to prompt endoscopy for dyspepsia symptom outcomes at one year (74% vs. 77% symptomatic at follow-up; RR 0.94, 95% CI 0.84–1.04), while substantially reducing endoscopy utilization and cost.[1]
A 2022 updated systematic review and meta-analysis (29 trials, 6,781 patients) confirmed that H. pylori eradication therapy provides statistically significant cure or improvement of functional dyspepsia symptoms, with the benefit particularly pronounced when eradication is confirmed.[6]
Repeat Testing After Eradication
Given that most patients with dyspepsia in primary care will have FD (rather than ulcer disease), the BSG (2022) guideline states that routine confirmatory testing to verify H. pylori eradication is not recommended after an initial course of eradication therapy in the typical primary care dyspepsia patient. Confirmatory testing should be reserved for patients at increased risk of gastric cancer (e.g., those from high-prevalence gastric cancer regions, those with a family history of gastric cancer, or prior documentation of peptic ulcer disease).[3]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017). "ACG and CAG Clinical Guideline: Management of Dyspepsia". Am J Gastroenterol. 112 (7): 988–1013. doi:10.1038/ajg.2017.154. PMID 28376465.
- ↑ 2.0 2.1 Park JH, Kim BJ, Oh CM, Kim MW, Shin CM (2024). "Global prevalence of functional dyspepsia according to Rome criteria, 1990–2020: a systematic review and meta-analysis". Sci Rep. 14 (1): 4396. doi:10.1038/s41598-024-54716-3. PMID 38404654 Check
|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, Hungin P, Overshott R, Vasant DH, Rudd S, Winning RC, Corsetti M, Ford AC (2022). "British Society of Gastroenterology guidelines on the management of functional dyspepsia". Gut. 71 (9): 1697–1723. doi:10.1136/gutjnl-2022-327737. PMID 35840388 Check
|pmid=value (help). - ↑ Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Schmulson M, Valdovinos MA (2025). "Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study". Aliment Pharmacol Ther. doi:10.1111/apt.70189. PMID 40547327 Check
|pmid=value (help). - ↑ "Suspected cancer: recognition and referral (NG12)". National Institute for Health and Care Excellence. 2015 (updated 2023). Retrieved 2024-01-01. Check date values in:
|date=(help) - ↑ Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut. 2022 Jan 12:gutjnl-2021-326583. doi: 10.1136/gutjnl-2021-326583. Epub ahead of print. PMID: 35022266.